Our analyses of TCGA data, which showed SEC62 alterations (mostly amplifications) in 32 tumor entities and shortened OS for patients with these alterations, support the potential role of SEC62 as a key tumor driver gene in various cancer entities, including breast cancer. Here, SEC62 is linked to neoplasm.